Royal Bank of Canada
APGE icon

Royal Bank of Canada’s Apogee Therapeutics APGE Stock Holding History

Royal Bank of Canada’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Sell
211
-927
-81% -$67.3K ﹤0.01% 5932
2025
Q4 		$85K Sell
1,138
-2,882
-72% -$182K ﹤0.01% 5281
2025
Q3 		$160K Buy
4,020
+3,935
+4,629% +$150K ﹤0.01% 5227
2025
Q2 		$4K Buy
85
+36
+73% +$1.37K ﹤0.01% 6669
2025
Q1 		$2K Sell
49
-727
-94% -$28.1K ﹤0.01% 6546
2024
Q4 		$35K Sell
776
-3,628
-82% -$185K ﹤0.01% 5858
2024
Q3 		$259K Buy
4,404
+1,002
+29% +$48K ﹤0.01% 4607
2024
Q2 		$134K Buy
3,402
+1,834
+117% +$89K ﹤0.01% 5070
2024
Q1 		$105K Sell
1,568
-4,841
-76% -$211K ﹤0.01% 5158
2023
Q4 		$179K Buy
6,409
+3,486
+119% +$69.9K ﹤0.01% 5192
2023
Q3 		$63K Buy
+2,923
New +$64.4K ﹤0.01% 5645

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Royal Bank of Canada's APGE Position: Q1 2026 in Review

Royal Bank of Canada reduced its Apogee Therapeutics (APGE) stake by 81% in Q1 2026, selling an estimated $67.3K and leaving 211 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #5932.

Royal Bank of Canada first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $259K in Q3 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Royal Bank of Canada held 211 shares of Apogee Therapeutics worth $18K as of Q1 2026.
  • Royal Bank of Canada sold 927 Apogee Therapeutics shares in Q1 2026, an estimated $67.3K.
  • Apogee Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5932 holding.
  • Royal Bank of Canada first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Royal Bank of Canada's Apogee Therapeutics position peaked at $259K in Q3 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.